Thomas Hope

MD

Radiologist
Radiologic therapy researcher and avid hiker

About me

Dr. Thomas Hope is a radiologist and nuclear medicine physician (an expert in medical applications of radioactive substances). He specializes in neuroendocrine tumors, with a focus on peptide receptor radionuclide therapy, which targets these cancer cells with a high dose of radiation. He has a special interest in molecular imaging and in treating cancer using the targeted, individualized techniques of precision medicine.

In addition to working with patients, Hope conducts research on novel radiopharmaceuticals, or new radioactive imaging substances that can help physicians locate tumors. He also works on combining different imaging modalities – such as positron emission tomography and MRI – to stage cancer in patients.

Hope received his medical degree from Stanford University School of Medicine. He completed a residency in diagnostic radiology at UCSF. He then completed a fellowship in nuclear medicine and body MRI at Stanford.

Hope is a member of the Radiological Society of North America, Society of Nuclear Medicine and Molecular Imaging, Society of Abdominal Radiology and International Society for Magnetic Resonance in Medicine.

  • Education

    Stanford University School of Medicine, 2007

  • Residencies

    UCSF Medical Center, Diagnostic Radiology, 2012

  • Fellowship

    Stanford Hospital and Clinics, Nuclear Medicine and Body MRI , 2013

  • Board Certifications

    Nuclear Medicine, American Board of Nuclear Medicine

  • Academic Title

    Associate Professor

Conditions I specialize in

Center for Neuroendocrine Tumors

Bakar Precision Cancer Medicine Building

1825 Fourth St.
San Francisco, CA 94158

(415) 476-2212
M-F, 8:30 a.m. - 5 p.m.

Gastrointestinal Medical Oncology Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Fourth Floor
San Francisco, CA 94158

(415) 353-9888
M-F, 8 a.m. - 5 p.m.

Selected research

Decorative Caduceus

Fluoroethyltyrosine in Detecting Tumors in Participants With Recurrent Intracranial Tumors

This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that have come back. Imaging agents, such as fluoroethyltyrosine,...

Recruiting

Decorative Caduceus

Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients

The investigators are imaging patients with prostate cancer using a new Positron Emission Tomography (PET) imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detect prostate cancer.

Recruiting

Contact me

Providers on my team

Share